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C hronic abdominal pain remains a major clinical challenge. Two typical chronic abdominal pain etiologies of visceral origin are chronic pancreatitis (CP) and postsurgical pain (PSP). Approximately 80%-90% of CP patients suffer from chronic abdominal pain during the course of their illness. 1, 2 Incidences of development of painful post-abdominal surgery vary in literature from 45% to 90%. [3] [4] [5] Intra-abdominal adhesions are believed to be the most likely cause of PSP. 4 CP and PSP are both associated with increased responsiveness of nociceptive pathways in the central nervous system, termed central sensitization. [6] [7] [8] Central sensitization produces pain hypersensitivity by changing the sensory response in the central nervous system and is associated with the development and maintenance of chronic pain. 7 Because central sensitization alters the properties of neurons in the central nervous system, the pain is frequently no longer reliably coupled to the presence of particular peripheral stimuli. Therefore, pharmacologic treatment options that produce analgesia by targeting these changes in the central nervous system are required. 8 The introduction of cannabinoids offers an interesting alternative for chronic pain management. Delta-9-tetrahydrocannabinol (THC) is the principal psychoactive compound of the Cannabis sativa plant 9 and interacts with 2 cannabinoid receptors, termed CB1 and CB2. CB1 receptors are predominantly found in the brain and spinal cord, and CB2 receptors are located primarily in the periphery, including the immune system. 10 CB1 receptors are also highly expressed in regions critical for emotion processing including the amygdala, hippocampus, and anterior cingulate cortex. 11 Brain activity within this emotion-related circuitry was found to be increased in patients with chronic pain. 12, 13 Hence, it was suggested that cannabinoids may modulate pain perception by disturbing the connectivity within this circuit. This was demonstrated by Lee et al, 14 who observed that THC reduced the functional connectivity between the amygdala and the primary somatosensory cortex (S1) during pain processing. Further research indicated that THC does not selectively affect these limbic regions but rather interferes with sensory processing, which in turn reduces sensory-limbic connectivity, leading to deactivation of affective regions. 15 Thus it may be expected that THC interferes, although not selectively, with the affective components of pain.
The majority of clinical trials on the efficacy of THC for pain treatment have been focused on cancer-related pain, central neuropathic pain syndromes, and acute pain conditions. [16] [17] [18] We aimed to investigate the efficacy, pharmacokinetics (PK), and safety of a novel cannabinoid-based product, an oral tablet containing purified natural THC, in patients with chronic abdominal pain.
Methods

Study Design
This phase II study used an equally randomized (allocation ratio 1:1), double-blind, placebo-controlled, parallel design. The study initially started as 2 clinical trials in (1) patients with painful CP and (2) patients with chronic abdominal PSP. Integration into 1 study was necessary because of a disappointing recruitment rate. Initial trials used identical study designs, treatment schemes, and outcome parameters. Integration was supported by an independent statistician who reviewed blinded interim data. The medical ethical committee approved both initial studies as well as the protocol amendment concerning study integration before study closure. The study was conducted according to the principles of the Declaration of Helsinki and in accordance with the International Conference on Harmonization guidelines of Good Clinical Practice. All subjects provided oral and written consent before conduct of any protocol-related procedures. All authors had access to the study data and had reviewed and approved the final manuscript. Clinicaltrials.gov identification numbers were NCT01562483 and NCT01551511.
Study Population
Adult patients (age >18 years) with abdominal pain that developed after a surgical procedure or resulting from CP were eligible for participation if they had persistent or intermittent abdominal pain (on a daily basis for at least 3 months) severe enough for medical treatment (average numeric rating scale [NRS] ! 3). 19 Key exclusion criteria were daily cannabis use in past 3 years, history of hypersensitivity to THC, serious painful conditions other than PSP or CP, significant medical disorder or concomitant medication that may interfere with the study or may pose a risk for the patient, major psychiatric illness in history, epileptic seizure in history, affected sensory input such as diabetic neuropathy, body mass index >36.0 kg/m 2 , significant exacerbation in illness within 2 weeks, positive urine drug screen or alcohol test at screening or on study days, clinically relevant abnormalities in electrocardiogram or laboratory results, pregnant or breastfeeding women, intending to conceive a child, or participation in another investigational drug study within 90 days before study entry. Preceding and during the entire study period, patients were asked to take their co-medication, including analgesics, according to prescription. Patients reported additional pain medication (taken as needed) in a diary. The study was executed at the Radboud University Medical Center, the Netherlands. Patients were recruited by their physician or via advertisements.
Randomization and Study Treatment
Tablets with standardized D9-THC content (Namisol; Echo Pharmaceuticals, Weesp, the Netherlands) or identical matching placebos were administered orally during a 50-day to 52-day add-on treatment. The study treatment consisted of 2 phases (Supplementary Figure 1) : a step-up phase (days 1-5: 3 mg 3 times a day [TID]; days 6-10: 5 mg TID) and a stable dose phase (days 11-52: 8 mg TID). It was permitted to taper the dosage to 5 mg TID when 8 mg was not tolerated. Independent pharmacists dispensed either active or placebo tablets according to a computergenerated randomization list stratified for opioid and non-opioid users by using separate lists. Treatment allocation was strictly concealed from participants, investigators, and all other study personnel involved in the study until end of study and database lock.
Study Procedures
Efficacy and safety assessments were conducted preceding medication intake on day 1 (visit 2), after 15 treatment days (visit 3), and 50-52 treatment days (visit 4). Several phone calls were performed by the investigators during and after the treatment period (days 4-5, 9-10, 21-23, 28-30, 38-40, and 59-61) to evaluate the tolerability, safety, and compliance. Additional study procedures are shown in the Supplementary Methods.
Primary Efficacy Outcome
The primary end point was change in pain intensity at the end of study treatment versus baseline of THC compared with placebo. A visual analogue scale (VAS) was used to quantify the mean (VAS mean ), minimal (VAS min ), and maximal (VAS max ) pain intensity in a daily diary, starting 5 days preceding first medication intake until the end of study treatment. The boundaries of these 10-cm lines were 0 for no pain and 10 for unbearable pain.
Statistics of Primary Outcome
VAS mean pain was analyzed by an analysis of covariance of the VAS mean at days 50-52 (last day of diary) between placebo and THC that incorporates VAS mean at baseline (mean day -5 to -1 pre-treatment) as covariate in the analyses. Possible moderating variables such as subpopulation (pancreatitis/postsurgical) and opiate user (y/n) were evaluated by observing potential interactions and post hoc subgroup analyses.
Secondary outcomes and statistics are fully described in Supplementary Methods.
Results
A total of 69 patients were assessed for eligibility during screening, of whom 65 were included and randomized (Supplementary Figure 2) . Sixty-two patients started study medication, of whom 21 patients (8 CP/13 PSP) in the THC arm and 29 patients (15 CP/14 PSP) in the placebo arm were included in the modified intentionto-treat efficacy analysis. For the safety analysis, 30 patients (12 CP/18 PSP) were included in the THC arm and 32 patients (15 CP/17 PSP) in the placebo arm. Patients characteristics are shown in Table 1 . Eligible patients were recruited from October 2012 to July 2014 and stopped because of poor recruitment.
Efficacy
For patients in the efficacy analyses, mean (standard deviation [SD]) VAS mean pain scores at baseline were 4.0 NOTE. Continuous data are expressed as mean (SD) and categorical data as numbers (n). Weak opioids were defined as codeine and tramadol. Strong opioids were defined as opioid-based therapies such as oxycontin, fentanyl, and morphine. NSAID, nonsteroidal anti-inflammatory drug; PCM, paracetamol.
(1.9) and 5.2 (1.8) for THC and placebo, respectively, and for patients in the safety analysis, including dropouts, 4.3 (1.9) and 5.2 (1.9) points, respectively. VAS mean pain scores during THC and placebo treatment are shown in Figure 1 . Primary efficacy analysis of the average VAS pain at the last day of diary did not reveal significant difference between THC and placebo treatment (95% Table 2 .
Secondary Efficacy Outcomes
No statistically significant differences were observed in pain-related questionnaires such as the patient global impression of change, pain catastrophizing, or pain-related anxiety. Measures of depression and generalized anxiety, quality of life, and treatment satisfaction also did not change after THC treatment compared with placebo. For the domain pain of the short-form 36 (SF-36) a trend was observed in favor of THC (F 1,47 ¼ 4.023; P ¼ .051). In addition, no differences were observed in subjective feelings corresponding to alertness, mood, and calmness or for psychedelic effects including difficulties in controlling thoughts, feeling high, and feeling drowsy for THC compared with placebo.
No statistically significant differences between THC and placebo were observed for appetite level. Subjects in the THC group gained on average 0.8 kg in weight, and patients in the placebo group lost on average 0.4 kg during study treatment (NS; F 1,47 ¼ 1.711; P ¼ .197). Balance disturbances were shown in several individuals but did not statistically increase during THC treatment compared with placebo.
Pharmacokinetics
PK samples on days 50-52 time-locked after medication intake were analyzed for 19 subjects (8 CP/11 PSP), resulting in 14 PK profiles of 8 mg and 5 PK profiles of 5 mg THC. Mean THC plasma concentration curves of THC and 11-OH-THC were plotted (Supplementary Figure 3) . Evaluation of the PK at an individual patient level revealed that some patients demonstrate a relatively late time to reach maximum plasma concentration (t max ) accompanied with a relatively low maximum concentration, which cannot be observed in the plasma concentration curves. Table 3 summarizes the calculated PK parameters of THC and 11-OH-THC. The t max of THC was 1.4 hours in patients on 8 mg TID compared with 1.8 hours in patients on 5 mg TID Namisol regimen, and the terminal half-life was 3.1 hours and 3.3 hours, respectively. Mean (AE SD) trough levels for THC were 0.70 (AE 0.59) ng/mL on day 15 and 0.57 (AE 0.32) ng/mL on days 50-52. One patient demonstrated pre-dose concentration levels below the lower limit of quantification on day 15.
Safety
Seven patients administered THC discontinued study treatment because of adverse events (AEs) compared with 2 patients in the placebo group. These patients did not tolerate a dosage of 5 mg TID THC and withdrew because of mild to moderate AEs. Another 5 patients in the THC arm, compared with 2 patients in the placebo arm, tapered their dosage to 5 mg TID.
A summary of (possibly) related AEs are presented in Table 4 . Five patients experienced serious AEs during the study treatment that were all considered not to be related to the study drug. Further AEs were mild or moderate. All subjects fully recovered from AEs. There were no clinically relevant changes in vital signs, electrocardiogram parameters, or safety laboratory parameters (hematology, biochemistry, and urinalysis).
Treatment Compliance
A mean (AE SD) of 97% (AE 4%) of all placebo study medication was taken correctly compared with 98% (AE 2%) in the THC treatment arm. There were no patients with a poor compliance (<75%), as measured by the amount of medication returned to the hospital after the treatment period. One subject appeared to be not compliant according to PK pre-dose levels on day 15 but demonstrated regular trough levels on day 50.
Discussion
This exploratory study evaluates the analgesic efficacy, PK, and tolerability of THC (1) by using an oral tablet with reliable bioavailability and blinding potential, (2) in patients with chronic abdominal pain, and (3) during a relatively long-lasting treatment period of 50 days.
Contrary to our hypothesis, THC did not show a beneficial effect on chronic abdominal pain compared with placebo. Similar results were observed for minimal and maximal reported VAS pain, indicating that THC does not affect background pain or pain peaks. It should be mentioned that despite the randomization procedure, patients in the THC group demonstrated pain of 1.2 points lower intensity at baseline than patients in the placebo group. In addition to the primary outcome, several questionnaires were used to evaluate a wide range of secondary efficacy outcomes during and after the THC treatment period. No differences were observed in pain-related questionnaires or measures of depression and anxiety, quality of life, and treatment satisfaction.
There are many reasons why clinical trials may fail to demonstrate analgesic efficacy on the primary end point. In the first instance, this could be related to insufficient analgesic potency of the investigational drug, but it may also be related to (1) an impaired bioavailability, (2) a large placebo response, (3) indirect analgesic effects, or (4) an inadequate study design. The absorption of orally administrated drugs might be affected particularly in patients with gastrointestinal deficits. 20 In the present study, mean plasma concentration curves of patients on both 5 mg as well as 8 mg TID treatment regimen demonstrate that THC was generally well-absorbed and further metabolized into 11-OH-THC. The t max of THC was 1.4 hours in patients on 8 mg TID compared with 1.8 hours in patients on 5 mg TID THC regimen. This delay in absorption in patients on 5 mg TID THC was accompanied with an enhanced terminal half-life duration, which overall resulted in comparable area under the curve (AUC) 0-tau between the 2 treatment regimens. It should be mentioned that the PK sampling until 6 hours after dose was too short for 2 patients on 5 mg TID THC to obtain all elimination parameters. Thus these parameters are probably an underestimation. However, the reliable PK profiles observed in our study population do not explain the lack of observed efficacy.
A large placebo response of 37% pain reduction was observed in the current study, which is common in chronic visceral pain studies. A meta-analysis including 8364 patients with irritable bowel syndrome allocated to placebo observed a pooled placebo response of 37.5%. 21 However, a previous randomized controlled trial (RCT) of our study group also observed a high reduction of average pain score by 24% in the placebo arm, but this did not prevent proof of superiority of pregabalin over placebo by using a very similar study design in patients with CP. 22 Underlying mechanisms of the placebo effect can be derived from psychological and neurobiological viewpoints. Two well-supported mechanisms from a psychological point of view are expectancy and conditioning. 23 Factors that influence the magnitude of the placebo response in RCTs include type of active medication, randomization ratio, and the number of planned face-to-face visits, thereby supporting the expectancy hypothesis. 24 High expectations toward treatment efficacy of THC might have contributed to the substantial placebo response as observed in the present study.
The lack of observed analgesic efficacy can also be considered from a mechanistic point of view. Two major mechanisms are currently proposed to underlie chronic pain and its development: (1) sensitization of nociceptive processing (central sensitization/hyperalgesia) and (2) alterations in central cognitive and autonomic processing. 8, 13 Consequently, the focus of treatment options for chronic pain has been shifting away from targeting the anatomic site to targeting changes in the peripheral and central nervous system. The anti-hyperalgesic potential of THC is not clearly demonstrated in humans and should be further evaluated by using measurements such as quantitative sensory testing or electroencephalography.
Patients with persistent pain demonstrated increased brain activity in areas considered to mediate emotion including the perigenual anterior cingulate cortex, the medial prefrontal cortex, and parts of the amygdala. 13 Thus, the representation of pain in the brain shifts over time to areas implicated in cognitive function, particularly emotion. 25 The frontal-limbic distribution of cannabinoid receptors in the brain suggests that cannabis may preferentially target the affective qualities of pain. A study conducted by Lee et al 14 demonstrated that dronabinol reduced the reported unpleasantness but not the intensity of ongoing pain and hyperalgesia. This suggests a shift in central nervous system function from nociceptive to cognitive, affective, and autonomic sensitization in patients moving from acute to chronic pain. Therefore, an agent targeting particular brain areas related to the cognitive emotional feature of chronic pain, such as THC, might be efficacious in our chronic pain population but might be better measured by using affective outcomes of pain.
In general, THC was well-tolerated, resulting in only mild to moderate (possibly) related AEs, which were similar to previous studies in CP patients and healthy volunteers. 26, 27 The considerable number of AEs reported in the placebo group as well as the withdrawal of patients because of AEs, despite being in the placebo arm, indicate that AEs were partly determined by nonpharmacologic effects. 28, 29 This so-called nocebo effect induces negative effects due to negative expectations. Cannabis is a generally well-known product, particularly as a recreational drug to induce desired psychotropic effects such as euphoria, relaxation, and perceptual alterations. Therefore, it is plausible that patients in this study were influenced by expectations, which may have influenced the occurrence of AEs.
A major limitation of the present study is the small sample size, which is insufficiently large to allow subgroup analyses. However, considering the CIs of the effect, it is doubtful that an increased sample size would have resulted in significant differences.
Furthermore, the present study comprises a heterogeneous patient population regarding etiology and anatomic site of the pain. However, all patients suffered from chronic abdominal pain, which is associated with central sensitization and alterations in central cognitive and autonomic processing. 8, 13 The presence of central sensitization in chronic pain patients supports the choice of treatments that reduce pain by normalizing hyperexcitable central neural activity, which makes the initial pain etiology or peripheral stimulus and past or currently received pain treatments less important. These variables and other patient characteristics might have contributed to interindividual differences in treatment effects, while on the other hand enhancing the generalizability of the study. In addition, it should be mentioned that most patients already had received different pain treatments including analgesics that failed to provide a satisfactory level of pain relief. Thus, this study included a selection of patients who did not respond to registered analgesics with a proven efficacy.
In summary, we conclude that THC treatment showed acceptable safety and tolerability profiles during a 50-day to 52-day add-on treatment period but did not significantly reduce pain scores or secondary efficacy outcomes in patients with chronic abdominal pain compared with placebo. Further research should evaluate the effects of THC on secondary and tertiary central pain processing.
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Supplementary Methods
Study Procedures
Potential participating patients were screened for eligibility within 7-35 days before start of study treatment (visit 1). Screening included demographics, medical history, concomitant medication, smoking habits, physical examination, 12-lead electrocardiogram, standard laboratory blood tests (hematology, biochemistry, virology), and urine screening tests (urinalysis, drug screening, and pregnancy test). Furthermore, all patients received a diary to report pain scores, add-on analgesics, and AEs.
Study days were carried out at the clinical research center of the Radboud University Medical Center, where each patient stayed in a separate quiet room.
Secondary Efficacy Outcomes
Pain-related questionnaires included the patient global impression of change (PGIC) 1 evaluated on days 15 and 50-52, pain catastrophizing scale 2,3 evaluated on days 1, 15, and 50-52, and pain anxiety symptom scale 4 evaluated on days 1 and 50-52. The hospital anxiety and depression scale 5 and quality of life questionnaire (RAND SF-36) 6 were filled out at days 1 and 50-52. Treatment satisfaction 7 and the patient appetite level (AppLe) were evaluated at the last study visit. The AppLe was a modification of the PGIC to evaluate any change in appetite in the last week and compare with before the study period.
Drug effects on alertness, mood, and calmness were explored by using the Bond and Lader questionnaire, and potential subjective psychotomimetic (psychedelic) effects were evaluated by using the Bowdle questionnaire. 8, 9 Both questionnaires were filled out on days 1, 4-5, 9-10, 15, and 50-52.
Left-right (roll) and anterior-posterior (pitch) postural movements were measured by using a gyroscope-based measurement system (SwayStar; Balance International Innovations GmbH, Iseltwald, Switzerland), which was attached to the waist of the patient. Patients stood, without shoes, as still as possible in a standardized base of support with their arms hanging at both sides of their body. Body sway was measured for 1 minute with eyes open, 1 minute with eyes closed, and for 30 seconds with eyes open standing on 1 leg of preference. Patients were asked to fixate at 1 point during the tasks with eyes open. The computerized measures used for analysis reflect the total angular area and 90% range roll and pitch excursion in degrees from the center of gravity.
Safety and Tolerability
Safety and tolerability were evaluated by using spontaneously reported AEs and measurements of vital functions, electrocardiogram, and laboratory tests. AEs were recorded in a daily diary, at study visits, and phone calls up to 2 weeks after study drug discontinuation. Blood pressure and heart rate were measured at screening and on both study days. Electrocardiogram, hematology, blood chemistry, and urinalysis were performed at screening and at the end of the study.
Pharmacokinetics
Plasma concentrations of THC and its active metabolite 11-OH-THC were determined pre-dose on days 1, 15, and 50-52 to confirm a baseline state, determine trough levels, and test the compliance. The PK sampling on days 50-52 was extended, with 7 additional samples time-locked after medication intake at 0:30, 1:00, 2:00, 3:00, 4:00, 5:00, and 5:55 hours after dose. Blood samples were collected in 4 mL ethylenediamine tetraacetic acid tubes and immediately after collection were wrapped in aluminum foil and kept on ice. Samples were centrifuged within 30 minutes at 2000g for 10 minutes at 4 C. The handling of THC samples was done to avoid direct light. The separated plasma was divided into primary and backup samples and stored at -80 C until bioanalysis. Bioanalysis (Analytisch Biochemisch Laboratorium b.v., Assen, the Netherlands) was performed by using a validated liquid chromatography/ mass spectrometry/mass spectrometry assay method according to good laboratory practice procedures. The lower limit of quantification for THC and 11-OH-THC was 0.100 ng mL À1 .
Statistical Analysis
The primary outcome of this study was change in pain intensity, measured by the VAS mean in a daily diary, between THC and placebo treatment. VAS mean pain was analyzed by an analysis of covariance of the VAS mean at days 50-52 (last day of diary) between placebo and THC that incorporates VAS mean at baseline (mean days -5 to -1 pre-treatment) as covariate in the analyses. Possible moderating variables such as subpopulation (pancreatitis/postsurgical) and opiate user (y/n) were evaluated by observing potential interactions and post hoc subgroup analyses. Secondary efficacy outcomes were analyzed in a similar manner. All participants who received the study medication for at least 36 days were included in the efficacy analyses according to the intention-to-treat principle. Dropouts before day 36 were replaced, and data of dropouts were excluded from further analyses for efficacy. Safety analyses were performed on all randomized subjects who received at least 1 dose of THC or placebo.
For statistical analysis SPSS software for Windows v.20 (Chicago, IL) was used. All statistical tests were performed two-tailed, and the limit for statistical significance was set at P < .05. The initial study in CP patients was powered (a ¼ 0.05, power ¼ 0.80) to detect a decrease of at least 1.0 VAS mean pain in the THC group compared with placebo, resulting in 34 patients per group. Variances in pain scores were extrapolated from a similar study with pregabalin. 10 No information was available to estimate the SD in the initial PSP study; therefore, same numbers were adopted for this study. Input variances for the integrated study were considered to be too unreliable to conduct a sample size calculation. Therefore, no sample size calculation was performed for this early phase 2 clinical trial.
Non-compartmental analysis to determine plasma PK parameters of the active compounds THC and 11-OH-THC was performed by using the WinNonlin modeling and analysis software (version 2.1 a; Pharsight Inc, Apex, NC). C max , t max , and the AUC from 0 up to the last measurement (AUC 0-last , using the linear log trapezoidal rule) were calculated from the individual plasma concentration-versus-time profiles. The terminal half-life was calculated only if there were 2 or more points (excluding C max ) in the elimination phase of the plasma concentration-time curve with r 2 > 0.80. For that reason, 1 patient was excluded from this part of the analysis for THC and 2 patients for 11-OH-THC. Subsequently, the areas under the plasma concentration curves extrapolated to the end of the dosing period (AUC tau ) were calculated by using the linear log trapezoidal rule and extrapolation to 8 hours.
